drugset / Trial / NCT01673724

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

NCT01673724

Phase 4 Completed 121 enrolled Sandoz
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether pramipexole and bromocriptine are effective in the treatment of non-motor symptoms in Parkinson's Disease.

Timeline

Start
2012-02
Primary completion
2016-05-23
Completion
2016-05-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bromocriptine Small molecule
Subject Pramipexole Unknown 0.125 mg
Subject Pramipexole Unknown 0.25 mg
Subject Pramipexole Unknown 0.5 mg
Subject Pramipexole Unknown 1 mg

Indications